Key result
Sodium-free potassium binders may be preferred in high cardiorenal risk patients to minimize sodium load.
For patients at high cardiorenal risk, managing hyperkalemia with newer potassium binders that do not add to the sodium load is preferred to maintain RAAS inhibitor therapy without exacerbating hypertension or heart failure.
Answers are grounded in this paper and cite their sources.
May support sodium-free binders in high cardiorenal risk; leaves open need for randomized confirmation before practice change.
High sodium intake, whether via diet or drugs, augments cardiorenal risk. Regardless of its source, high sodium intake can both lead to hypertension and reduce the efficacy of renin-angiotensin-aldosterone system inhibitors, which are currently guideline-recommended treatments for hypertension, chronic kidney disease, and heart failure. Reducing sodium intake is therefore recommended to reduce the risk of adverse cardiorenal outcomes. An inverse relationship exists between sodium and potassium, with foods high in sodium being lower in potassium. Diets high in potassium have been associated with reducing hypertension and heart failure; however, optimal renin-angiotensin-aldosterone system inhibitor dosing is often limited by hyperkalemia, which can lead to life-threatening cardiac arrhythmias and increased mortality. Potassium binders are effective at reducing potassium levels. Although some use sodium as the potassium exchange ion, thus increasing sodium intake, a new potassium binder uses another exchange ion and therefore does not increase sodium intake. When treatment options require agents that may precipitate hyperkalemia, particularly in patients at high cardiorenal risk, drugs that do not add to the sodium load may be preferred. A literature search was conducted using PubMed; search terms included potassium, sodium, hyperkalemia, potassium binders, and the literature search focused on manuscripts published more recently since 2000.
No takes yet. Share an insight, caveat, or question.
Clegg et al. (2017) conducted a review in Cardiovascular disease and hyperkalemia. Potassium binders without sodium exchange ion vs. Potassium binders with sodium exchange ion was evaluated. Potassium binders that do not use sodium as an exchange ion may be preferred for managing hyperkalemia in patients at high cardiorenal risk to avoid increasing sodium load.
Synapse has enriched 10 related papers. Consider them for comparative context: